Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Abnormal epileptogenic neural circuit" refers to pathological changes in brain networks that predispose individuals to recurrent unprovoked seizures characteristic of epilepsy. These abnormalities arise from an imbalance between excitation and inhibition within neuronal networks, leading to excessive synchronization and hypersynchronous firing. The process by which normal brain tissue becomes capable of generating spontaneous seizures is called epileptogenesis. This transformation can be triggered by genetic factors or acquired insults such as traumatic brain injury, stroke, infection, or prolonged seizures. The resulting aberrant circuitry involves maladaptive neurogenesis and synaptic reorganization—such as miswiring of new neurons—which contribute to hyperexcitability[1][2]. While this concept is central to understanding the pathophysiology of epilepsy at a systems level[3], it does not represent a discrete molecular target but rather describes dysfunctional network properties.\n\n> “The end results of the epileptogenic process are best understood as abnormalities of neuronal circuitry and not simply as molecular or cellular abnormalities... The neuronal network models conceive [epilepsy] as being due to results of abnormalities in the neuronal circuitry.”[1]\n\n> “Epileptogenesis... encompasses the transformation of neuronal networks following an initial insult... resulting in a brain capable of generating spontaneous recurrent seizures.”[2]\n\nNote: \nThis entry does not correspond to a single molecule/receptor/protein but instead describes pathological changes at the level of entire neural circuits/networks. Therefore it should be flagged as incorrect for structured drug-target databases focused on canonical molecules/receptors/enzymes/channels.
Modulation of neuronal excitability (e.g., via sodium channel blockers, GABAergic enhancers)\nInhibition of hypersynchronous firing\n(These mechanisms are indirect and act on components within the abnormal circuits rather than the circuit itself.)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Abnormal epileptogenic neural circuit.